Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

• A. Rodríguez-Lescure ^[1] ; F. A. de la Peña ^[7] ; E. Aranda ^[2] ; A. Calvo ^[3] ; E. Felip ^[4] ; P. Garrido ^[5] ; R. Vera ^[6]
  1. [1] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  2. [2] Hospital Reina Sofía

     Hospital Reina Sofía

     Tudela, España

     
  3. [3] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  4. [4] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  5. [5] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  6. [6] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  7. [7] Hospital Universitario Morales Meseguer

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 12 (December), 2020, págs. 2253-2263
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Purpose The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed.

    Methods A questionnaire was sent to 146 hospitals in Spain to collect information on the process of approval of 11 oncology drugs of an unquestionable clinical benefit and five predictive biomarkers of mandatory determination for specific treatments.

    Results Results highlight the still existing differences in the access of oncology drugs, as well as the newly identified differences in the access to predictive biomarkers between Autonomous Communities (AACC) in Spain, as well as between different hospitals within the same Autonomous Community.

    Conclusions The SEOM considers it necessary to reduce the differences identified, increase homogeneity, and improve conditions of access to oncology drugs and biomarkers, and makes proposals to address these issues.